Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

NCT01254734 | Terminated DMC

• 2 other identifiers: 09206NCI-2010-02169
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Transoral robotic surgery (TORS) is a less invasive type of surgery for head and neck cancer and may have fewer side effects and improve recovery. PURPOSE: This clinical trial studies how transoral robotic surgery works in treating patients with benign or stage I-IV head and neck cancer.

Conditions

Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity

Outcome Measures

Primary Outcomes (6)

• Assessment of the feasibility of Transoral Robotic Surgery (TORS) in improving transoral accessibility within the upper aerodigestive tract in patients with benign or malignant head and neck tumors

  From 6 months to 3 years after completion of study treatment

• Assessment of the total operative time to perform transoral surgery using TORS in patients with benign or malignant head and neck tumors

  From 6 months to 3 years after completion of study treatment

• Assessment of blood loss during transoral surgery using TORS in patients with benign or malignant head and neck tumors

  From 6 months to 3 years after completion of study treatment

• Assessment of hospitalization time of in patients with benign or malignant head and neck tumors undergoing transoral surgery using TORS

  From 6 months to 3 years after completion of study treatment

• Assessment of the need to convert to an open procedure during transoral surgery using TORS in patients with benign or malignant head and neck tumors

  From 6 months to 3 years after completion of study treatment

• Assessment of complications of transoral surgery using TORS in patients with benign or malignant head and neck tumors

  From 6 months to 3 years after completion of study treatment

Secondary Outcomes (2)

• Collection of data on oncologic outcomes, disease free survival, local control rate and overall survival.

  From 6 months to 3 years after completion of study treatment

• Assessment of quality of life outcomes in patients undergoing TORS using patient-report outcomes instruments

  From 6 months to 3 years after completion of study treatment

Study Arms (1)

Arm I

EXPERIMENTAL

Patients undergo transoral robotic microsurgery.

Procedure: transoral robotic surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment

Interventions

transoral robotic surgery PROCEDURE

Undergo transoral robotic microsurgery

Arm I

laboratory biomarker analysis OTHER

Correlative studies

Arm I

quality-of-life assessment PROCEDURE

Ancillary studies

Also known as: quality of life assessment

Arm I

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients clinical, radiologic or pathologic evidence of a benign or malignant tumor in the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, retropharynx or parapharyngeal space
• Surgical access is amenable to treatment with conventional transoral surgical procedures
• ASA (American Society of Anesthesiologists) performance status (PS) of 1-4 or ECOG (Eastern Cooperative Oncology Group) PS 0-3, thereby including a population that stands to gain the most from a minimally invasive surgical approach
• Patients should have no serious acute infection
• Patients must sign a study-specific informed consent form

You may not qualify if:

• Evidence of distant metastases (below the clavicle) by clinical or radiographic measures
• ASA score \> 4; ECOG PS score \> 3
• Pregnancy (during first or 3rd trimester - due to risks of anesthesia)
• The presence of medical conditions which contraindicate general anesthesia
• Unexplained fever or untreated, active infection
• Inability to obtain exposure to allow performance of the planned transoral surgical procedure
• Proposed surgical site with history of prior treatment: radiation
• Tumor adherent to carotid artery or jugular vein
• Fixation to pre-vertebral tumor
• Mandibular invasion

Sponsors & Collaborators

• City of Hope Medical Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

City of Hope Medical Center

Duarte, California, 91010, United States

Location

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Study Officials

• Ellie Maghami

  City of Hope Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 3, 2010
• First Posted: December 7, 2010
• Study Start: April 1, 2011
• Primary Completion: November 1, 2014
• Study Completion: November 1, 2014
• Last Updated: November 10, 2014

Record last verified: 2014-11

Locations

US (1)